Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) have been associated with significant cardiovascular and renal benefits including prevention of heart failure (HF), renal failure and cardiovascular mortality, and have been recommended for the treatment of patients with T2DM at risk for or with established cardiovascular disease 8. The gene discussed is SLC5A2; the disease is cardiovascular disorder.